Valuation ratios measure the quantity of an asset or flaw (e.g., earnings) associated with ownership of a specified claim (e.g., a share of ownership of the enterprise).
Paying user area
Try for free
Medtronic PLC pages available for free this week:
- Common-Size Income Statement
- Analysis of Profitability Ratios
- Analysis of Short-term (Operating) Activity Ratios
- Enterprise Value to FCFF (EV/FCFF)
- Operating Profit Margin since 2005
- Debt to Equity since 2005
- Price to Earnings (P/E) since 2005
- Price to Book Value (P/BV) since 2005
- Analysis of Debt
- Aggregate Accruals
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Medtronic PLC for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Current Valuation Ratios
Medtronic PLC | Abbott Laboratories | Cigna Group | CVS Health Corp. | Elevance Health Inc. | Humana Inc. | Intuitive Surgical Inc. | UnitedHealth Group Inc. | Health Care Equipment & Services | Health Care | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data | |||||||||||||
Current share price (P) | |||||||||||||
No. shares of common stock outstanding | |||||||||||||
Growth rate (g) | |||||||||||||
Earnings per share (EPS) | |||||||||||||
Next year expected EPS | |||||||||||||
Operating profit per share | |||||||||||||
Sales per share | |||||||||||||
Book value per share (BVPS) | |||||||||||||
Valuation Ratios (Price Multiples) | |||||||||||||
Price to earnings (P/E) | |||||||||||||
Price to next year expected earnings | |||||||||||||
Price-earnings-growth (PEG) | |||||||||||||
Price to operating profit (P/OP) | |||||||||||||
Price to sales (P/S) | |||||||||||||
Price to book value (P/BV) |
Based on: 10-K (reporting date: 2024-04-26).
If the company price multiple is lower then the price multiple of benchmark then company stock is relatively undervalued.
Otherwise, if the company price multiple is higher then the price multiple of benchmark then company stock is relatively overvalued.
Historical Valuation Ratios (Summary)
Apr 26, 2024 | Apr 28, 2023 | Apr 29, 2022 | Apr 30, 2021 | Apr 24, 2020 | Apr 26, 2019 | ||
---|---|---|---|---|---|---|---|
Price to earnings (P/E) | |||||||
Price to operating profit (P/OP) | |||||||
Price to sales (P/S) | |||||||
Price to book value (P/BV) |
Based on: 10-K (reporting date: 2024-04-26), 10-K (reporting date: 2023-04-28), 10-K (reporting date: 2022-04-29), 10-K (reporting date: 2021-04-30), 10-K (reporting date: 2020-04-24), 10-K (reporting date: 2019-04-26).
Valuation ratio | Description | The company |
---|---|---|
P/E ratio | The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings. | Medtronic PLC P/E ratio increased from 2022 to 2023 but then slightly decreased from 2023 to 2024. |
P/OP ratio | Because P/E ratio is calculated using net income, the ratio can be sensitive to nonrecurring earnings and capital structure, analysts may use price to operating profit. | Medtronic PLC P/OP ratio increased from 2022 to 2023 but then decreased significantly from 2023 to 2024. |
P/S ratio | An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. | Medtronic PLC P/S ratio increased from 2022 to 2023 but then decreased significantly from 2023 to 2024. |
P/BV ratio | The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company required rate of return and its actual rate of return. | Medtronic PLC P/BV ratio increased from 2022 to 2023 but then decreased significantly from 2023 to 2024. |
Price to Earnings (P/E)
Apr 26, 2024 | Apr 28, 2023 | Apr 29, 2022 | Apr 30, 2021 | Apr 24, 2020 | Apr 26, 2019 | ||
---|---|---|---|---|---|---|---|
No. shares of common stock outstanding1 | |||||||
Selected Financial Data (US$) | |||||||
Net income attributable to Medtronic (in millions) | |||||||
Earnings per share (EPS)2 | |||||||
Share price1, 3 | |||||||
Valuation Ratio | |||||||
P/E ratio4 | |||||||
Benchmarks | |||||||
P/E Ratio, Competitors5 | |||||||
Abbott Laboratories | |||||||
Cigna Group | |||||||
CVS Health Corp. | |||||||
Elevance Health Inc. | |||||||
Humana Inc. | |||||||
Intuitive Surgical Inc. | |||||||
UnitedHealth Group Inc. | |||||||
P/E Ratio, Sector | |||||||
Health Care Equipment & Services | |||||||
P/E Ratio, Industry | |||||||
Health Care |
Based on: 10-K (reporting date: 2024-04-26), 10-K (reporting date: 2023-04-28), 10-K (reporting date: 2022-04-29), 10-K (reporting date: 2021-04-30), 10-K (reporting date: 2020-04-24), 10-K (reporting date: 2019-04-26).
1 Data adjusted for splits and stock dividends.
2 2024 Calculation
EPS = Net income attributable to Medtronic ÷ No. shares of common stock outstanding
= ÷ =
3 Closing price as at the filing date of Medtronic PLC Annual Report.
4 2024 Calculation
P/E ratio = Share price ÷ EPS
= ÷ =
5 Click competitor name to see calculations.
Valuation ratio | Description | The company |
---|---|---|
P/E ratio | The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings. | Medtronic PLC P/E ratio increased from 2022 to 2023 but then slightly decreased from 2023 to 2024. |
Price to Operating Profit (P/OP)
Apr 26, 2024 | Apr 28, 2023 | Apr 29, 2022 | Apr 30, 2021 | Apr 24, 2020 | Apr 26, 2019 | ||
---|---|---|---|---|---|---|---|
No. shares of common stock outstanding1 | |||||||
Selected Financial Data (US$) | |||||||
Operating profit (in millions) | |||||||
Operating profit per share2 | |||||||
Share price1, 3 | |||||||
Valuation Ratio | |||||||
P/OP ratio4 | |||||||
Benchmarks | |||||||
P/OP Ratio, Competitors5 | |||||||
Abbott Laboratories | |||||||
Cigna Group | |||||||
CVS Health Corp. | |||||||
Elevance Health Inc. | |||||||
Humana Inc. | |||||||
Intuitive Surgical Inc. | |||||||
UnitedHealth Group Inc. | |||||||
P/OP Ratio, Sector | |||||||
Health Care Equipment & Services | |||||||
P/OP Ratio, Industry | |||||||
Health Care |
Based on: 10-K (reporting date: 2024-04-26), 10-K (reporting date: 2023-04-28), 10-K (reporting date: 2022-04-29), 10-K (reporting date: 2021-04-30), 10-K (reporting date: 2020-04-24), 10-K (reporting date: 2019-04-26).
1 Data adjusted for splits and stock dividends.
2 2024 Calculation
Operating profit per share = Operating profit ÷ No. shares of common stock outstanding
= ÷ =
3 Closing price as at the filing date of Medtronic PLC Annual Report.
4 2024 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= ÷ =
5 Click competitor name to see calculations.
Valuation ratio | Description | The company |
---|---|---|
P/OP ratio | Because P/E ratio is calculated using net income, the ratio can be sensitive to nonrecurring earnings and capital structure, analysts may use price to operating profit. | Medtronic PLC P/OP ratio increased from 2022 to 2023 but then decreased significantly from 2023 to 2024. |
Price to Sales (P/S)
Apr 26, 2024 | Apr 28, 2023 | Apr 29, 2022 | Apr 30, 2021 | Apr 24, 2020 | Apr 26, 2019 | ||
---|---|---|---|---|---|---|---|
No. shares of common stock outstanding1 | |||||||
Selected Financial Data (US$) | |||||||
Net sales (in millions) | |||||||
Sales per share2 | |||||||
Share price1, 3 | |||||||
Valuation Ratio | |||||||
P/S ratio4 | |||||||
Benchmarks | |||||||
P/S Ratio, Competitors5 | |||||||
Abbott Laboratories | |||||||
Cigna Group | |||||||
CVS Health Corp. | |||||||
Elevance Health Inc. | |||||||
Humana Inc. | |||||||
Intuitive Surgical Inc. | |||||||
UnitedHealth Group Inc. | |||||||
P/S Ratio, Sector | |||||||
Health Care Equipment & Services | |||||||
P/S Ratio, Industry | |||||||
Health Care |
Based on: 10-K (reporting date: 2024-04-26), 10-K (reporting date: 2023-04-28), 10-K (reporting date: 2022-04-29), 10-K (reporting date: 2021-04-30), 10-K (reporting date: 2020-04-24), 10-K (reporting date: 2019-04-26).
1 Data adjusted for splits and stock dividends.
2 2024 Calculation
Sales per share = Net sales ÷ No. shares of common stock outstanding
= ÷ =
3 Closing price as at the filing date of Medtronic PLC Annual Report.
4 2024 Calculation
P/S ratio = Share price ÷ Sales per share
= ÷ =
5 Click competitor name to see calculations.
Valuation ratio | Description | The company |
---|---|---|
P/S ratio | An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. | Medtronic PLC P/S ratio increased from 2022 to 2023 but then decreased significantly from 2023 to 2024. |
Price to Book Value (P/BV)
Apr 26, 2024 | Apr 28, 2023 | Apr 29, 2022 | Apr 30, 2021 | Apr 24, 2020 | Apr 26, 2019 | ||
---|---|---|---|---|---|---|---|
No. shares of common stock outstanding1 | |||||||
Selected Financial Data (US$) | |||||||
Shareholders’ equity (in millions) | |||||||
Book value per share (BVPS)2 | |||||||
Share price1, 3 | |||||||
Valuation Ratio | |||||||
P/BV ratio4 | |||||||
Benchmarks | |||||||
P/BV Ratio, Competitors5 | |||||||
Abbott Laboratories | |||||||
Cigna Group | |||||||
CVS Health Corp. | |||||||
Elevance Health Inc. | |||||||
Humana Inc. | |||||||
Intuitive Surgical Inc. | |||||||
UnitedHealth Group Inc. | |||||||
P/BV Ratio, Sector | |||||||
Health Care Equipment & Services | |||||||
P/BV Ratio, Industry | |||||||
Health Care |
Based on: 10-K (reporting date: 2024-04-26), 10-K (reporting date: 2023-04-28), 10-K (reporting date: 2022-04-29), 10-K (reporting date: 2021-04-30), 10-K (reporting date: 2020-04-24), 10-K (reporting date: 2019-04-26).
1 Data adjusted for splits and stock dividends.
2 2024 Calculation
BVPS = Shareholders’ equity ÷ No. shares of common stock outstanding
= ÷ =
3 Closing price as at the filing date of Medtronic PLC Annual Report.
4 2024 Calculation
P/BV ratio = Share price ÷ BVPS
= ÷ =
5 Click competitor name to see calculations.
Valuation ratio | Description | The company |
---|---|---|
P/BV ratio | The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company required rate of return and its actual rate of return. | Medtronic PLC P/BV ratio increased from 2022 to 2023 but then decreased significantly from 2023 to 2024. |